Urokinase in Hypertensive Capsuloganglionic Hemorrhage with Intraventricular Hemorrhage: A Randomized Control Trial
Background: Capsuloganglionic hemorrhage with intraventricular hemorrhage (IVH) is always associated with higher mortality and morbidity [12]. So, we did a randomized control trail in patients requiring External ventricular Drain (EVD) for hypertensive IVH with and without instilling Urokinase; to k...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
National Board of Examinations
2025-07-01
|
| Series: | National Board of Examinations Journal of Medical Sciences |
| Subjects: | |
| Online Access: | https://natboard.edu.in/ejournal/articledtl?x=dmJTbkpqV1I1R1hmcWQ4Z1pqS1ZCQT09 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background: Capsuloganglionic hemorrhage with intraventricular hemorrhage (IVH) is always associated with higher mortality and morbidity [12]. So, we did a randomized control trail in patients requiring External ventricular Drain (EVD) for hypertensive IVH with and without instilling Urokinase; to know it’s effectiveness [19]. Methods: A computerized randomized controlled trial was carried out on 30 patients who needed EVD for hypertensive capsuloganglionic hemorrhage with IVH. Patients were randomly assigned to one of two groups: test (EVD + urokinase) or control (EVD only). Graeb scores, Glasgow Outcome Scale (GOS), ICU stay, GCS, and complications were compared before and after treatment. Results: The EVD + urokinase group had better functional outcomes, a shorter ICU stay (5.8 vs. 7.8 days, p=0.044), and a much larger drop in Graeb scores (p<0.001). There was no increased risk of infection or rebleeding. Conclusion: In Hypertensive Capsuloganglionic Hemorrhage with IVH, intraventricular fibrinolysis with urokinase is a safe and effective to improve the outcome of the patient. |
|---|---|
| ISSN: | 2583-7524 |